The Billion-Dollar Drug Built on a Paper That No Longer Exists
The NEJM just retracted the pivotal trial paper for Tavneos, a vasculitis drug with nearly half a billion in annual sales. The reason: patient data was secretly changed after the trial was unblinded, and nobody disclosed it.
Imagine buying a house, moving your family in, and then learning the home inspection was faked. That's roughly where the biotech world finds itself with Tavneos (avacopan), a vasculitis drug whose foundational clinical study just got yanked from the most prestigious medical journal on the planet.
The New England Journal of Medicine retracted the pivotal ADVOCATE trial paper for Tavneos, a drug that pulled in $459 million in global sales in 2023 and was on track to cross $600 million. The reason? Key patient data was secretly changed after the trial was supposed to be locked and done. And nobody told anyone.
Nine Patients, One Very Big Problem
To understand why this matters, you need a quick crash course in how clinical trials work. When a drug trial finishes collecting data, researchers "lock" the database. Think of it like sealing a ballot box after voting closes. Nobody gets to go back in and change things. Especially not after unblinding, which is when everyone finds out who got the real drug and who got the placebo.
But that's exactly what happened here. Primary endpoint assessments for nine patients were re-evaluated after the database was locked and after the trial was unblinded. And this little detail never made it into the published paper.
NJEM called this "inconsistent with proper research conduct." That's the academic equivalent of slamming the table.
The retraction was actually requested by the study's two academic authors, David Jayne and Peter Merkel, after an ongoing FDA investigation surfaced the issue. Reports indicate the FDA had raised concerns that unblinded personnel may have manipulated efficacy results. That's not a typo in a footnote; that's the kind of problem that unravels everything.
What Tavneos Was Supposed to Be
Tavneos had a genuinely compelling story. ANCA-associated vasculitis (AAV) is a rare autoimmune disease where the body's immune system attacks its own blood vessels, damaging kidneys and other organs. The standard treatment involves dumping patients with high-dose steroids (prednisone), which work but carry brutal side effects: weight gain, bone loss, diabetes, infections. It's like putting out a fire with a flamethrower.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Tavneos offered a different approach. It's an oral pill that blocks the C5a receptor, a molecular switch in the complement system (part of the immune system's first-response team). The ADVOCATE trial tested whether Tavneos plus standard immunosuppression could replace prolonged steroid use.
The results, as originally published, looked strong. At 26 weeks, 72.3% of Tavneos patients hit remission compared to 70.1% on the prednisone taper. That met the bar for noninferiority (basically proving it was at least as good). At 52 weeks, Tavneos pulled ahead: 65.7% sustained remission versus 54.9%, achieving genuine superiority. Patients on Tavneos also used fewer steroids and had better kidney recovery.
It was a feel-good win for rare disease patients. The FDA approved Tavneos in October 2021, though even then the advisory committee votes were mixed — tied 9 to 9 on efficacy, and 10 to 8 on both safety and overall benefit-risk. Amgen liked the story enough to buy the drug's developer, ChemoCentryx, for $3.7 billion in 2022.
The Cracks Were Already Showing
The NEJM retraction didn't come out of nowhere. There was a correction back in January 2024 about glucocorticoid dose conversions. That was a tremor. The retraction is the earthquake.
And it's not the only front where Tavneos is under fire. Post-market safety reports have linked the drug to serious liver injuries, including fatal drug-induced liver injury and a rare condition called vanishing bile duct syndrome. When your efficacy data is questioned and new safety signals are emerging, you're fighting on two fronts with dwindling ammunition.
The FDA has reportedly already called for the drug's withdrawal from the U.S. market. Amgen has pushed back, and an independent re-adjudication of the trial data is supposedly due by June 29, 2026. Across the Atlantic, the European Medicines Agency's advisory committee (the CHMP) has recommended revoking the EU marketing authorization entirely. CSL, which markets Tavneos in Europe, has stopped starting new patients and guided to just $145 million in revenue for fiscal year 2026 in its territories.
That's a long way from $600 million peak sales projections.
Why This Retraction Is Almost Unprecedented
Journal retractions happen. But retracting the pivotal trial paper for a drug that's already on the market is extraordinarily rare. It's one thing to pull a paper about a drug still in development. It's something else entirely when thousands of patients are already taking it and billions in revenue are flowing.
A retraction doesn't automatically mean the drug stops working. The pill itself hasn't changed. But it removes the published evidence from the citable scientific record, which means clinicians, guideline committees, and insurers can no longer point to the ADVOCATE paper as reliable proof that Tavneos works.
For regulators, the retraction strengthens the argument that the original approval was built on compromised data. If the endpoint assessments were changed after unblinding, the entire efficacy result is tainted. It's like finding out the referee changed the score after the game ended: maybe the right team still won, but you can't trust the final tally.
What Happens to Patients Now?
This is the part that stings. AAV is rare and serious. Treatment options are limited. For patients who feel better on Tavneos, the regulatory and scientific chaos is deeply unsettling. Doctors who prescribed the drug in good faith are now stuck in an uncomfortable limbo.
Amgen's independent re-adjudication could, in theory, confirm that the original efficacy findings hold up even without the questionable endpoint changes. If those results come in clean, there's a path (narrow as it may be) to keeping Tavneos alive. But if they don't, or if the FDA decides the broader data package is too compromised, we could see an approved drug pulled from the market based on research misconduct. That almost never happens.
The Bigger Picture
The Tavneos saga is a stress test for the entire system. Peer review at the world's top journal didn't catch the undisclosed data changes. The FDA's original advisory committee was already split nearly down the middle. Post-market surveillance flagged liver problems the trial didn't. It took years and a federal investigation to surface what went wrong.
For biotech investors, the lesson is uncomfortably clear: a $3.7 billion acquisition price doesn't buy you certainty. For patients, it's a reminder that the system, while imperfect, does eventually self-correct, even if "eventually" takes five years. And for the scientific community, the Tavneos retraction raises a question that will echo for a long time: if this can happen to a paper in the NEJM, supporting an FDA-approved drug, what else might be hiding in the published record?
Deals & M&A5 min read
GSK Just Lit $700 Million on Fire (and Walked Away)
GSK just terminated its $2.2 billion Alzheimer's partnership with Alector after both drugs flopped in clinical trials. The $700 million upfront payment is gone forever, and the wreckage tells us a lot about why the brain remains drug development's toughest frontier.
